How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It …
Category:
News
-
-
Introduction: How NICE Approval in the NHS Is Now Secured Securing approval from the National Institute for Health and Care Excellence (NICE) remains one of the most decisive milestones for …
-
Why SNOMED CT and dm+d changes matter fundamentally for Digital Health, MedTech, and Biotech companies Between 2025 and 2026, the NHS will quietly implement one of the most consequential digital …
-
Denmark is often described as a “DRG country”. That is technically true but strategically misleading. On the surface, the Danish DRG system looks familiar: national groupers, published tariffs, annual updates, …
-
Introduction: Why Netherlands Surgical Reimbursement Works Differently Securing Netherlands surgical reimbursement is unlike any other European market. The Dutch system links reimbursement directly to minimum-volume standards, hospital authorisation, and insurer …
-
German Hospital Reform 2025 German Hospital Reform 2025 marks a fundamental shift in how hospitals secure DRG eligibility, structure their service portfolios, and stabilise their finances. For more than two …
-
Pharmaceutical Reimbursement in Poland: A 2025 Deep Dive Poland’s pharmaceutical reimbursement system remains one of Europe’s most structured, evidence-driven, and economically disciplined models. For manufacturers, health-economics teams, and policy specialists, …
-
Introduction Why Reimbursement Analysis Fails to Give You an Accurate Picture of MedTech Funding In every DRG-based health system — whether Germany’s G-DRG, France’s GHS, the UK’s NHS Payment Scheme, …
-
This article reviews the most important biotech news this week, highlighting the breakthrough approval of Bayer’s non-hormonal menopause drug Lynkuet and the major clinical failure faced by Alector in frontotemporal …
-
France has entered a new, more disciplined era in the governance of diagnostic innovation—an era in which public funding is tied directly to evidence, real-world performance, and measurable system-level value, …